Olsi Gjyshi

Olsi Gjyshi

Auto-generated profile, based on publicly available information

Olsi Gjyshi

The University of Texas MD Anderson Cancer Center, Houston, TX

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2021 in Journal of Thoracic Oncology
Verified
Journal Article
Closed access
OGOlsi Gjyshi
Olsi Gjyshi
TXTing Xu
Ting Xu
AEAdnan Elhammali
Adnan Elhammali
DBDavid Boyce-Fappiano
David Boyce-Fappiano
SCStephen G. Chun
Stephen G. Chun
ZLZhongxing Liao
Zhongxing Liao

1 December 2021 in JCO Oncology Practice
Verified
Journal Article
Open access
DBDavid Boyce-Fappiano
David Boyce-Fappiano
KNKevin A. Nguyen
Kevin A. Nguyen
OGOlsi Gjyshi
Olsi Gjyshi
GMGohar Manzar
Gohar Manzar
CAChike O. Abana
Chike O. Abana
ACAlbert J. Chang
Albert J. Chang
PURPOSE: Cervical cancer (CC) disproportionately affects minorities who have higher incidence and mortality rates. Standard of care for locally advanced CC involves a multimodality approach including brachytherapy (BT), which independently improves oncologic outcomes. Here, we examine the impact of insurance status and race on BT utilization with the SEER database. MATERIALS AND METHODS: In total, 7,266 patients with stage I-IV CC diagnosed from 2007 to 2015 were included. BT utilization, overall survival (OS), and disease-specific survival (DSS) were compared. RESULTS: Overall, 3,832 (52.7%) received combined external beam radiation therapy (EBRT) + BT, whereas 3,434 (47.3%) received EBRT alone. On multivariate logistic regression analysis, increasing age (OR, 0.98; 95% CI, 0.98 to 0.99; P < .001); Medicaid (OR, 0.80; 95% CI, 0.72 to 0.88; P < .001), uninsured (OR, 0.67; 95% CI, 0.56 to 0.80; P < .001), and unknown versus private insurance (OR, 0.61; 95% CI, 0.43 to 0.86; P < .001); Black (OR, 0.68; 95% CI, 0.60 to 0.77; P < .001) and unknown versus White race (OR, 0.30; 95% CI, 0.13 to 0.77; P = .047); and American Joint Committee on Cancer stage II (OR, 1.07; 95% CI, 0.93 to 1.24; P = .36), stage III (OR, 0.82; 95% CI, 0.71 to 0.94; P = .006), stage IV (OR, 0.30; 95% CI, 0.23 to 0.40; P < .001), and unknown stage versus stage I (OR, 0.36; 95% CI, 0.28 to 0.45; P < .001) were associated with decreased BT utilization. When comparing racial survival differences, the 5-year OS was 44.2% versus 50.9% ( P < .0001) and the 5-year DSS was 55.6% versus 60.5% ( P < .0001) for Black and White patients, respectively. Importantly, the racial survival disparities resolved when examining patients who received combined EBRT + BT, with the 5-year OS of 57.3% versus58.5% ( P = .24) and the 5-year DSS of 66.3% versus 66.6% ( P = .53) for Black and White patients, respectively. CONCLUSION: This work demonstrates notable inequities in BT utilization for CC that particularly affects patients of lower insurance status and Black race, which translates into inferior oncologic outcomes. Importantly, the use of BT was able to overcome racial survival differences, thus highlighting its essential value.

20 August 2019 in British Journal of Radiology
Verified
Journal Article
Open access
OGOlsi Gjyshi
Olsi Gjyshi
ZLZhongxing Liao
Zhongxing Liao
Radiation therapy is an essential component of treatment for locally advanced non-small cell lung cancer (NSCLC) but can be technically challenging because of the proximity of lung tumors to nearby critical organs or structures. The most effective strategy for reducing radiation-induced toxicity is to reduce unnecessary exposure of normal tissues by using advanced technology; examples from photon (X-ray) therapy have included three-dimensional conformal radiation therapy versus its predecessor, two-dimensional radiation therapy, and intensity-modulated photon radiation therapy versus its predecessor, three-dimensional conformal therapy. Using particle-beam therapy rather than photons offers the potential for further advantages because of the unique depth-dose characteristics of the particles, which can be exploited to allow still higher dose escalation to tumors with greater sparing of normal tissues, with the ultimate goal of improving local tumor control and survival while preserving quality of life by reducing treatment-related toxicity. However, the costs associated with particle therapy with protons are considerably higher than the current state of the art in photon technology, and evidence of clinical benefit from protons is increasingly being demanded to justify the higher financial burden on the healthcare system. Some such evidence is available from preclinical studies, from retrospective, single-institution clinical series, from analyses of national databases, and from single-arm prospective studies in addition to several ongoing randomized comparative trials. This review summarizes the rationale for and challenges of using proton therapy to treat thoracic cancers, reviews the current clinical experience, and suggests topics for future research.

2 August 2019 in JAMA Network Open
Verified
Journal Article
Open access
PDF file
OGOlsi Gjyshi
Olsi Gjyshi
ELEthan Ludmir
Ethan Ludmir
TPTodd A. Pezzi
Todd A. Pezzi
DBDavid Boyce-Fappiano
David Boyce-Fappiano
ADAmy E. Dursteler
Amy E. Dursteler
SLSteven Lin
Steven Lin
The recent phase 3 trial by Takahashi et al1 showed no overall survival benefit with prophylactic cranial irradiation (PCI) over active magnetic resonance imaging (MRI) surveillance among patients with extensive-stage small cell lung cancer (ES-SCLC), questioning the previously established benefit of PCI for this patient group.2 Consequently, in 2018, the National Comprehensive Cancer Network3 established equipoise between MRI surveillance and PCI in ES-SCLC. These developments have fueled debate over the role of PCI in this setting, and current practice patterns remain unclear.4 We conducted a nationwide survey study of radiation oncologists (ROs) to assess changes in the use of PCI for patients with ES-SCLC following publication of the trial by Takahashi et al.1

1 May 2020 in Journal of Neuro-Oncology
Verified
Journal Article
Closed access
PDF file
OGOlsi Gjyshi
Olsi Gjyshi
DBDavid Boyce-Fappiano
David Boyce-Fappiano
TPTodd A. Pezzi
Todd A. Pezzi
ELEthan B. Ludmir
Ethan B. Ludmir
LXLianchun Xiao
Lianchun Xiao
AGAmol J Ghia
Amol J Ghia

1 December 2021 in JCO Oncology Practice
Verified
Journal Article
Closed access
DBDavid Boyce-Fappiano
David Boyce-Fappiano
MNMatthew S. Ning
Matthew S. Ning
OGOlsi Gjyshi
Olsi Gjyshi
SMShane Mesko
Shane Mesko
DPDario Pasalic
Dario Pasalic
NTNikhil G. Thaker
Nikhil G. Thaker